{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:45:11Z","timestamp":1775259911372,"version":"3.50.1"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bcp.2024.116507","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T03:47:50Z","timestamp":1724471270000},"page":"116507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Therapeutic potential of relaxin or relaxin mimetics in managing cardiovascular complications of diabetes"],"prefix":"10.1016","volume":"229","author":[{"given":"Arun George","family":"Devasia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meyammai","family":"Shanmugham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adaikalavan","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Bellanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen Huei","family":"Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116507_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/ars.2018.7706","article-title":"Nitric oxide resistance, induced in the myocardium by diabetes, is circumvented by the nitric oxide redox sibling, nitroxyl","volume":"32","author":"Qin","year":"2020","journal-title":"Antioxid. Redox Signal."},{"issue":"11","key":"10.1016\/j.bcp.2024.116507_b0015","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic Mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: an old but still the best treatment for type 2 diabetes","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetol. Metab. Syndr."},{"issue":"4","key":"10.1016\/j.bcp.2024.116507_b0030","doi-asserted-by":"crossref","first-page":"840","DOI":"10.5114\/aoms.2015.53304","article-title":"Sulfonylureas and their use in clinical practice","volume":"11","author":"Sola","year":"2015","journal-title":"Arch. Med. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bcp.2024.116507_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109146","article-title":"Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with\/without albuminuria: A systematic review and network meta-analysis","volume":"183","author":"Kawai","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"issue":"22","key":"10.1016\/j.bcp.2024.116507_b0050","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1111\/bph.16236","article-title":"Therapeutic targets of fibrosis: Translational advances and current challenges","volume":"180","author":"De Blasio","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116507_b0055","doi-asserted-by":"crossref","DOI":"10.1177\/17539447231210170","article-title":"A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy","volume":"17","author":"Dhar","year":"2023","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"22","key":"10.1016\/j.bcp.2024.116507_b0060","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1111\/bph.15820","article-title":"Current challenges in the treatment of cardiac fibrosis: Recent insights into the sex-specific differences of glucose-lowering therapies on the diabetic heart: IUPHAR Review 33","volume":"180","author":"Sharma","year":"2023","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2024.116507_b0065","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/dom.14108","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis","volume":"22","author":"Mantsiou","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"10.1016\/j.bcp.2024.116507_b0070","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1111\/dom.15185","article-title":"All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes","volume":"25","author":"Riley","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.bcp.2024.116507_b0075","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11906-011-0231-x","article-title":"Effects of relaxin on arterial dilation, remodeling, and mechanical properties","volume":"13","author":"Conrad","year":"2011","journal-title":"Curr. Hypertens. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2024.116507_b0080","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12464","article-title":"From pregnancy to cardiovascular disease: lessons from relaxin-deficient animals to understand relaxin actions in the vascular system","volume":"26","author":"Jelinic","year":"2019","journal-title":"Microcirculation"},{"issue":"10","key":"10.1016\/j.bcp.2024.116507_b0085","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/bph.13614","article-title":"Vascular actions of relaxin: nitric oxide and beyond","volume":"174","author":"Leo","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2024.116507_b0090","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bph.13523","article-title":"The actions of relaxin on the human cardiovascular system","volume":"174","author":"Sarwar","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116507_b0095","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/biolre\/iox023","article-title":"Relaxin treatment reduces angiotensin II-induced vasoconstriction in pregnancy and protects against endothelial dysfunction","volume":"96","author":"Marshall","year":"2017","journal-title":"Biol. Reprod."},{"issue":"9","key":"10.1016\/j.bcp.2024.116507_b0100","doi-asserted-by":"crossref","first-page":"R847","DOI":"10.1152\/ajpregu.00506.2015","article-title":"Relaxin deficiency attenuates pregnancy-induced adaptation of the mesenteric artery to angiotensin II in mice","volume":"310","author":"Marshall","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116507_b0105","doi-asserted-by":"crossref","first-page":"R753","DOI":"10.1152\/ajpregu.00276.2017","article-title":"Peptide hormone relaxin: from bench to bedside","volume":"314","author":"Jelinic","year":"2018","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.semnephrol.2010.10.003","article-title":"Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia","volume":"31","author":"Conrad","year":"2011","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.bcp.2024.116507_b0115","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coph.2019.04.001","article-title":"Recent developments in relaxin mimetics as therapeutics for cardiovascular diseases","volume":"45","author":"Leo","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116507_b0120","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.tips.2016.04.001","article-title":"Serelaxin: A novel therapeutic for vascular diseases","volume":"37","author":"Leo","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2024.116507_b0125","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fphar.2018.00501","article-title":"Relaxin as a therapeutic target for the cardiovascular complications of diabetes","volume":"9","author":"Ng","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116507_b0130","first-page":"H285","article-title":"Increased superoxide production and altered nitric oxide-mediated relaxation in the aorta of young but not old male relaxin-deficient mice","volume":"309","author":"Ng","year":"2015","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1096\/fj.13-233429","article-title":"Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment","volume":"28","author":"Jelinic","year":"2014","journal-title":"FASEB J."},{"issue":"13","key":"10.1016\/j.bcp.2024.116507_b0140","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1096\/fj.06-6263com","article-title":"Evidence for local relaxin ligand-receptor expression and function in arteries","volume":"20","author":"Novak","year":"2006","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.bcp.2024.116507_b0145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cardfail.2010.08.011","article-title":"The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of G(i)-phosphoinositide-3 kinase signaling","volume":"17","author":"Dschietzig","year":"2011","journal-title":"J. Card. Fail."},{"issue":"5","key":"10.1016\/j.bcp.2024.116507_b0150","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/sj.bjp.0704922","article-title":"Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin","volume":"137","author":"Kompa","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0155","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1152\/physrev.00001.2012","article-title":"Relaxin family peptides and their receptors","volume":"93","author":"Bathgate","year":"2013","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/pr.58.1.9","article-title":"International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides","volume":"58","author":"Bathgate","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2024.116507_b0165","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1152\/ajpregu.00156.2011","article-title":"Maternal vasodilation in pregnancy: the emerging role of relaxin","volume":"301","author":"Conrad","year":"2011","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.bcp.2024.116507_b0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.mce.2019.01.015","article-title":"Relaxin and extracellular matrix remodeling: Mechanisms and signaling pathways","volume":"487","author":"Ng","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2024.116507_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114884","article-title":"Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directions","volume":"197","author":"Samuel","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2024.116507_b0180","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bph.13529","article-title":"Anti-fibrotic actions of relaxin","volume":"174","author":"Samuel","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116507_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116130","article-title":"The involvement of the Wnt\/\u03b2-catenin signaling cascade in fibrosis progression and its therapeutic targeting by relaxin","volume":"223","author":"Somanader","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2024.116507_b0190","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/labinvest.2010.198","article-title":"Relaxin remodels fibrotic healing following myocardial infarction","volume":"91","author":"Samuel","year":"2011","journal-title":"Lab. Invest."},{"key":"10.1016\/j.bcp.2024.116507_b0195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijcard.2017.09.017","article-title":"Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties","volume":"250","author":"Beiert","year":"2018","journal-title":"Int. J. Cardiol."},{"issue":"9","key":"10.1016\/j.bcp.2024.116507_b0200","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1210\/en.2004-0209","article-title":"Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo","volume":"145","author":"Samuel","year":"2004","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.bcp.2024.116507_b0205","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1161\/01.HYP.0000171930.00697.2f","article-title":"Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats","volume":"46","author":"Lekgabe","year":"2005","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.bcp.2024.116507_b0210","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.hrthm.2015.12.030","article-title":"Relaxin suppresses atrial fibrillation in aged rats by reversing fibrosis and upregulating Na+ channels","volume":"13","author":"Henry","year":"2016","journal-title":"Heart Rhythm"},{"issue":"3","key":"10.1016\/j.bcp.2024.116507_b0215","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/CIRCRESAHA.113.301646","article-title":"Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts","volume":"113","author":"Parikh","year":"2013","journal-title":"Circ. Res."},{"issue":"11","key":"10.1016\/j.bcp.2024.116507_b0220","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.34067\/KID.0002722021","article-title":"Relaxin attenuates organ fibrosis via an angiotensin type 2 receptor mechanism in aged hypertensive female rats","volume":"2","author":"Barsha","year":"2021","journal-title":"Kidney360"},{"issue":"9","key":"10.1016\/j.bcp.2024.116507_b0225","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.7150\/thno.38640","article-title":"Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1","volume":"10","author":"Wilhelmi","year":"2020","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.bcp.2024.116507_b0230","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1210\/en.2008-0250","article-title":"Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy","volume":"149","author":"Samuel","year":"2008","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0235","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12020-018-1534-3","article-title":"Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes","volume":"60","author":"Arag\u00f3n-Herrera","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.bcp.2024.116507_b0240","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fphar.2017.00141","article-title":"Serelaxin treatment reduces oxidative stress and increases aldehyde dehydrogenase-2 to attenuate nitrate tolerance","volume":"8","author":"Leo","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116507_b0245","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1210\/en.2006-1324","article-title":"Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes","volume":"148","author":"Moore","year":"2007","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.bcp.2024.116507_b0250","article-title":"Human relaxin-2 (serelaxin) attenuates oxidative stress in cardiac muscle cells exposed in vitro to hypoxia-reoxygenation. evidence for the involvement of reduced glutathione up-regulation","volume":"9","author":"Nistri","year":"2020","journal-title":"Antioxidants (Basel)"},{"issue":"2","key":"10.1016\/j.bcp.2024.116507_b0255","article-title":"Serelaxin protects H9c2 cardiac myoblasts against hypoxia and reoxygenation-induced damage through activation of AMP kinase\/sirtuin1: further insight into the molecular mechanisms of the cardioprotection of this hormone","volume":"13","author":"Zizi","year":"2024","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0260","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.1038\/s41598-019-53867-y","article-title":"Relaxin reverses maladaptive remodeling of the aged heart through Wnt-signaling","volume":"9","author":"Martin","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2024.116507_b0265","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/bs.vh.2020.12.017","article-title":"Relaxin abrogates genomic remodeling of the aged heart","volume":"115","author":"Romero","year":"2021","journal-title":"Vitam. Horm."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190935","article-title":"Relaxin reverses inflammatory and immune signals in aged hearts","volume":"13","author":"Martin","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bcp.2024.116507_b0275","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/bph.13404","article-title":"Time-dependent activation of prostacyclin and nitric oxide pathways during continuous i.v. infusion of serelaxin (recombinant human H2 relaxin)","volume":"173","author":"Leo","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2024.116507_b0280","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1161\/01.CIR.0000025630.05387.45","article-title":"Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart?","volume":"106","author":"Fisher","year":"2002","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.bcp.2024.116507_b0285","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/HYPERTENSIONAHA.110.165027","article-title":"Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans","volume":"57","author":"McGuane","year":"2011","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.bcp.2024.116507_b0290","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1210\/en.2010-1126","article-title":"Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide","volume":"152","author":"McGuane","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2024.116507_b0295","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3389\/fphys.2018.01234","article-title":"RXFP1 receptor activation by relaxin-2 induces vascular relaxation in mice via a G\u03b1(i2)-protein\/PI3K\u00df\/\u03b3\/nitric oxide-coupled pathway","volume":"9","author":"Lian","year":"2018","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0300","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000493","article-title":"Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation","volume":"3","author":"Leo","year":"2014","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0305","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41443-022-00653-6","article-title":"In vitro effect of relaxin in the rat corpus cavernosum under hyperglycemic and normoglycemic conditions","volume":"36","author":"Acar-Sahan","year":"2024","journal-title":"Int J Impot Res"},{"issue":"10","key":"10.1016\/j.bcp.2024.116507_b0310","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/02713683.2020.1737714","article-title":"Ocular phenotype of relaxin gene knockout (Rln(-\/-)) mice","volume":"45","author":"Hampel","year":"2020","journal-title":"Curr. Eye Res."},{"issue":"4","key":"10.1016\/j.bcp.2024.116507_b0315","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10792-018-0884-4","article-title":"Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats","volume":"39","author":"Hampel","year":"2019","journal-title":"Int. Ophthalmol."},{"issue":"12","key":"10.1016\/j.bcp.2024.116507_b0320","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/01.RES.0000104086.43830.6C","article-title":"Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries","volume":"93","author":"Jeyabalan","year":"2003","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.bcp.2024.116507_b0325","doi-asserted-by":"crossref","first-page":"R349","DOI":"10.1152\/ajpregu.00635.2001","article-title":"Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats","volume":"283","author":"Novak","year":"2002","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0330","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.RES.0000051884.27117.7E","article-title":"Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1\/2 and nuclear factor-kappaB","volume":"92","author":"Dschietzig","year":"2003","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0335","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/cvr\/cvs149","article-title":"Relaxin improves TNF-\u03b1-induced endothelial dysfunction: the role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling","volume":"95","author":"Dschietzig","year":"2012","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.bcp.2024.116507_b0340","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12371","article-title":"Short-term (48 hours) intravenous serelaxin infusion has no effect on myogenic tone or vascular remodeling in rat mesenteric arteries","volume":"24","author":"Jelinic","year":"2017","journal-title":"Microcirculation"},{"key":"10.1016\/j.bcp.2024.116507_b0345","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.peptides.2013.08.020","article-title":"Impaired effect of relaxin on vasoconstrictor reactivity in spontaneous hypertensive rats","volume":"49","author":"van Drongelen","year":"2013","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.bcp.2024.116507_b0350","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1161\/HYPERTENSIONAHA.110.164392","article-title":"Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(\u03c9)-nitro-L-arginine methyl ester hypertensive rats","volume":"58","author":"Sasser","year":"2011","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.bcp.2024.116507_b0355","doi-asserted-by":"crossref","first-page":"F1355","DOI":"10.1152\/ajprenal.00407.2014","article-title":"Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension","volume":"307","author":"Sasser","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"5","key":"10.1016\/j.bcp.2024.116507_b0360","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/HYPERTENSIONAHA.109.149369","article-title":"Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats","volume":"55","author":"Xu","year":"2010","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.bcp.2024.116507_b0365","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1096\/fj.13-230797","article-title":"Treatment for cerebral small vessel disease: effect of relaxin on the function and structure of cerebral parenchymal arterioles during hypertension","volume":"27","author":"Chan","year":"2013","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0370","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/bph.14858","article-title":"Relaxin reduces endothelium-derived vasoconstriction in hypertension: revealing new therapeutic insights","volume":"177","author":"Leo","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2024.116507_b0375","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/jcmm.12802","article-title":"Protection from cigarette smoke-induced vascular injury by recombinant human relaxin-2 (serelaxin)","volume":"20","author":"Pini","year":"2016","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bcp.2024.116507_b0380","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.atherosclerosis.2016.06.008","article-title":"Anti-atherosclerotic effects of serelaxin in apolipoprotein E-deficient mice","volume":"251","author":"Tiyerili","year":"2016","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.bcp.2024.116507_b0385","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/1753-0407.12521","article-title":"Macro- and microvascular endothelial dysfunction in diabetes","volume":"9","author":"Shi","year":"2017","journal-title":"J. Diabetes"},{"issue":"3","key":"10.1016\/j.bcp.2024.116507_b0390","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/pharmrev.120.000096","article-title":"Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies","volume":"73","author":"Xu","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"7","key":"10.1016\/j.bcp.2024.116507_b0395","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jne.12161","article-title":"Microglia are selectively activated in endocrine and cardiovascular control centres in streptozotocin-induced diabetic rats","volume":"26","author":"Rana","year":"2014","journal-title":"J. Neuroendocrinol."},{"issue":"13","key":"10.1016\/j.bcp.2024.116507_b0400","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310705","article-title":"Endothelial dysfunction in diabetes mellitus: new insights","volume":"24","author":"Dubsky","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0405","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/157016112798829797","article-title":"Diabetes mellitus and vascular endothelial dysfunction: current perspectives","volume":"10","author":"Tousoulis","year":"2012","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0410","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/apha.12646","article-title":"Endothelial dysfunction and vascular disease \u2013 a 30th anniversary update","volume":"219","author":"Vanhoutte","year":"2017","journal-title":"Acta Physiol (Oxf.)"},{"key":"10.1016\/j.bcp.2024.116507_b0415","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.phrs.2016.03.011","article-title":"Serelaxin (recombinant human relaxin-2) prevents high glucose-induced endothelial dysfunction by ameliorating prostacyclin production in the mouse aorta","volume":"107","author":"Ng","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2024.116507_b0420","doi-asserted-by":"crossref","DOI":"10.1038\/srep39604","article-title":"Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of type 1 diabetes","volume":"7","author":"Ng","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2024.116507_b0425","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejphar.2016.03.043","article-title":"The endothelial cyclooxygenase pathway: Insights from mouse arteries","volume":"780","author":"Luo","year":"2016","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2024.116507_b0430","first-page":"H319","article-title":"Vasoconstrictor role of cyclooxygenase-1-mediated prostacyclin synthesis in non-insulin-dependent diabetic mice induced by high-fat diet and streptozotocin","volume":"307","author":"Zhu","year":"2014","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"key":"10.1016\/j.bcp.2024.116507_b0435","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.phrs.2016.06.025","article-title":"Adverse vascular remodelling is more sensitive than endothelial dysfunction to hyperglycaemia in diabetic rat mesenteric arteries","volume":"111","author":"Kahlberg","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.bcp.2024.116507_b0440","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1476-5381.2010.01023.x","article-title":"Impairment of both nitric oxide-mediated and EDHF-type relaxation in small mesenteric arteries from rats with streptozotocin-induced diabetes","volume":"162","author":"Leo","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"2\u20133","key":"10.1016\/j.bcp.2024.116507_b0445","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejphar.2011.03.018","article-title":"3',4'-Dihydroxyflavonol restores endothelium-dependent relaxation in small mesenteric artery from rats with type 1 and type 2 diabetes","volume":"659","author":"Leo","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116507_b0450","first-page":"H502","article-title":"Short-term type 1 diabetes alters the mechanism of endothelium-dependent relaxation in the rat carotid artery","volume":"299","author":"Leo","year":"2010","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"key":"10.1016\/j.bcp.2024.116507_b0455","article-title":"Diabetes attenuates the contribution of endogenous nitric oxide but not nitroxyl to endothelium dependent relaxation of rat carotid arteries","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116507_b0460","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041384","article-title":"The novel small-molecule annexin-A1 mimetic, compound 17b, elicits vasoprotective actions in streptozotocin-induced diabetic mice","volume":"21","author":"Marshall","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2024.116507_b0465","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.2337\/db13-0033","article-title":"Relaxin treatment reverses insulin resistance in mice fed a high-fat diet","volume":"62","author":"Bonner","year":"2013","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.bcp.2024.116507_b0470","doi-asserted-by":"crossref","first-page":"e20813","DOI":"10.1371\/journal.pone.0020813","article-title":"3',4'-Dihydroxyflavonol reduces superoxide and improves nitric oxide function in diabetic rat mesenteric arteries","volume":"6","author":"Leo","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.bcp.2024.116507_b0475","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1096\/fj.10-175471","article-title":"Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-\u03b3","volume":"25","author":"Chan","year":"2011","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.bcp.2024.116507_b0480","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00424-010-0807-3","article-title":"Endothelial dysfunction in diabetes: multiple targets for treatment","volume":"459","author":"Ding","year":"2010","journal-title":"Pflugers Arch."},{"issue":"6","key":"10.1016\/j.bcp.2024.116507_b0485","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/FJC.0000000000000180","article-title":"Flavonols in the prevention of diabetes-induced vascular dysfunction","volume":"65","author":"Leo","year":"2015","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2024.116507_b0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107382","article-title":"A vasoactive role for endogenous relaxin in mesenteric arteries of male mice","volume":"9","author":"Leo","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bcp.2024.116507_b0495","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.bbrc.2019.03.112","article-title":"H2 relaxin ameliorates angiotensin II-induced endothelial dysfunction through inhibition of excessive mitochondrial fission","volume":"512","author":"Gao","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.bcp.2024.116507_b0500","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1042\/CS20130105","article-title":"Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice","volume":"125","author":"Bitto","year":"2013","journal-title":"Clin. Sci. (Lond.)"},{"issue":"1 Suppl","key":"10.1016\/j.bcp.2024.116507_b0505","first-page":"66","article-title":"Porcine derived relaxin stimulates new vessel formation and improves the disturbed wound healing of the genetically diabetic mice","volume":"118","author":"Squadrito","year":"2013","journal-title":"Ital. J. Anat. Embryol."},{"issue":"5","key":"10.1016\/j.bcp.2024.116507_b0510","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1524-475X.2000.00361.x","article-title":"Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites","volume":"8","author":"Unemori","year":"2000","journal-title":"Wound Repair Regen."},{"issue":"5","key":"10.1016\/j.bcp.2024.116507_b0515","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-0043-116946","article-title":"Relaxin inhibits cardiac fibrosis in diabetic rats: roles of protein kinase C\u03b4","volume":"126","author":"Wang","year":"2018","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"3","key":"10.1016\/j.bcp.2024.116507_b0520","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/BF03346460","article-title":"Effects of recombinant human relaxin upon proliferation of cardiac fibroblast and synthesis of collagen under high glucose condition","volume":"32","author":"Wang","year":"2009","journal-title":"J. Endocrinol. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0525","first-page":"691","article-title":"Relaxin ameliorates high glucose-induced cardiomyocyte hypertrophy and apoptosis via the Notch1 pathway","volume":"15","author":"Wei","year":"2018","journal-title":"Exp. Ther. Med."},{"issue":"5","key":"10.1016\/j.bcp.2024.116507_b0530","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063896","article-title":"Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-\u03b2\/Smad3 signaling","volume":"8","author":"Sassoli","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0535","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000368484","article-title":"Relaxin-2 does not ameliorate nephropathy in an experimental model of type-1 diabetes","volume":"40","author":"Dschietzig","year":"2015","journal-title":"Kidney Blood Press. Res."},{"issue":"9","key":"10.1016\/j.bcp.2024.116507_b0540","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2174\/0929866511320090009","article-title":"The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes","volume":"20","author":"Wong","year":"2013","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.bcp.2024.116507_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114578","article-title":"Relaxin elicits renoprotective actions accompanied by increasing bile acid levels in streptozotocin-induced diabetic mice","volume":"162","author":"Leo","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0550","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1038\/s41467-024-46829-0","article-title":"Trimethylamine N-oxide impairs \u03b2-cell function and glucose tolerance","volume":"15","author":"Kong","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2024.116507_b0555","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040504","article-title":"Gut-derived metabolite, trimethylamine-N-oxide (TMAO) in cardio-metabolic diseases: detection, mechanism, and potential therapeutics","volume":"16","author":"Shanmugham","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0560","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46820-7","article-title":"Time-dependent specific molecular signatures of inflammation and remodelling are associated with trimethylamine-N-oxide (TMAO)-induced endothelial cell dysfunction","volume":"13","author":"Shanmugham","year":"2023","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2024.116507_b0565","article-title":"PGC-1\u03b1 is a master regulator of mitochondrial lifecycle and ROS stress response","volume":"12","author":"Abu Shelbayeh","year":"2023","journal-title":"Antioxidants (Basel)"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2024.116507_b0570","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.mce.2009.08.014","article-title":"Relaxin signaling activates peroxisome proliferator-activated receptor gamma","volume":"315","author":"Singh","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"issue":"2","key":"10.1016\/j.bcp.2024.116507_b0575","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1074\/jbc.M114.589325","article-title":"Relaxin activates peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) through a pathway involving PPAR\u03b3 coactivator 1\u03b1 (PGC1\u03b1)","volume":"290","author":"Singh","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116507_b0580","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.phrs.2019.04.009","article-title":"Serelaxin (recombinant human relaxin-2) treatment affects the endogenous synthesis of long chain poly-unsaturated fatty acids and induces substantial alterations of lipidome and metabolome profiles in rat cardiac tissue","volume":"144","author":"Arag\u00f3n-Herrera","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.bcp.2024.116507_b0585","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002620RR","article-title":"Relaxin has beneficial effects on liver lipidome and metabolic enzymes","volume":"35","author":"Arag\u00f3n-Herrera","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2024.116507_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116157","article-title":"Human recombinant relaxin-2 (serelaxin) regulates the proteome, lipidome, lipid metabolism and inflammatory profile of rat visceral adipose tissue","volume":"223","author":"Arag\u00f3n-Herrera","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116507_b0595","article-title":"Cardiovascular effects of relaxin-2: therapeutic potential and future perspectives","author":"Almeida-Pinto","year":"2023","journal-title":"Clin. Res. Cardiol."},{"issue":"5","key":"10.1016\/j.bcp.2024.116507_b0600","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1586\/17512433.2015.1073587","article-title":"Serelaxin a novel treatment for acute heart failure","volume":"8","author":"Castrini","year":"2015","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0605","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/1755-5922.12231","article-title":"Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence","volume":"35","author":"Ghosh","year":"2017","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.bcp.2024.116507_b0610","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1749-6632.2008.03819.x","article-title":"First clinical experience with intravenous recombinant human relaxin in compensated heart failure","volume":"1160","author":"Dschietzig","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9673","key":"10.1016\/j.bcp.2024.116507_b0615","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","article-title":"Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study","volume":"373","author":"Teerlink","year":"2009","journal-title":"Lancet"},{"issue":"9860","key":"10.1016\/j.bcp.2024.116507_b0620","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bcp.2024.116507_b0625","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1801291","article-title":"Effects of serelaxin in patients with acute heart failure","volume":"381","author":"Metra","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116507_b0630","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cbpa.2014.09.014","article-title":"Synthetic relaxins","volume":"22","author":"Hossain","year":"2014","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bcp.2024.116507_b0635","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mce.2019.01.008","article-title":"Single chain peptide agonists of relaxin receptors","volume":"487","author":"Praveen","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116507_b0640","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1039\/C5SC04754D","article-title":"A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1","volume":"7","author":"Hossain","year":"2016","journal-title":"Chem. Sci."},{"issue":"8","key":"10.1016\/j.bcp.2024.116507_b0645","doi-asserted-by":"crossref","first-page":"e015748","DOI":"10.1161\/JAHA.119.015748","article-title":"B7\u201333, a functionally selective relaxin receptor 1 agonist, attenuates myocardial infarction-related adverse cardiac remodeling in mice","volume":"9","author":"Devarakonda","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.bcp.2024.116507_b0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114370","article-title":"The single-chain relaxin mimetic, B7\u201333, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy","volume":"160","author":"Alam","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2024.116507_b0655","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejphar.2017.05.005","article-title":"B7\u201333 replicates the vasoprotective functions of human relaxin-2","volume":"807","author":"Marshall","year":"2017","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116507_b0660","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/acs.jmedchem.0c01533","article-title":"Identification of potent and long-acting single-chain peptide mimetics of human relaxin-2 for cardiovascular diseases","volume":"64","author":"Mallart","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0665","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1021\/acs.bioconjchem.8b00764","article-title":"Design and synthesis of potent, long-acting lipidated relaxin-2 analogs","volume":"30","author":"Muppidi","year":"2019","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0670","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24716-2","article-title":"Characterization of a new potent and long-lasting single chain peptide agonist of RXFP1 in cells and in vivo translational models","volume":"12","author":"Illiano","year":"2022","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.bcp.2024.116507_b0675","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612670","article-title":"Further developments towards a minimal potent derivative of human relaxin-2","volume":"24","author":"Handley","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2024.116507_b0680","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076616","article-title":"A lipidated single-B-chain derivative of relaxin exhibits improved in vitro serum stability without altering activity","volume":"24","author":"Praveen","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116507_b0685","doi-asserted-by":"crossref","DOI":"10.1111\/bph.16338","article-title":"R2R01: A long-acting single-chain peptide agonist of RXFP1 for renal and cardiovascular diseases","author":"Poirier","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"15","key":"10.1016\/j.bcp.2024.116507_b0690","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/bph.16055","article-title":"Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failure","volume":"180","author":"Verdino","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116507_b0695","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae112","article-title":"Volenrelaxin (LY3540378) increases renal plasma flow: A randomized phase 1 trial","author":"Tham","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"issue":"10","key":"10.1016\/j.bcp.2024.116507_b0700","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/bph.13656","article-title":"Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1","volume":"174","author":"Agoulnik","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2024.116507_b0705","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1021\/acs.biochem.5b01195","article-title":"Structural insights into the activation of human relaxin family peptide receptor 1 by small-molecule agonists","volume":"55","author":"Hu","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2024.116507_b0710","unstructured":"J. Xiao, C.Z. Chen, Z. Huang, I.U. Agoulnik, M. Ferrer, N. Southall, X. Hu, W. Zheng, A.I. Agoulnik, J.J. Marugan, Discovery, optimization, and biological activity of the first potent and selective small-molecule agonist series of human relaxin receptor 1 (RXFP1), Probe Reports from the NIH Molecular Libraries Program, National Center for Biotechnology Information (US), Bethesda (MD), 2010."},{"key":"10.1016\/j.bcp.2024.116507_b0715","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/ncomms2953","article-title":"Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1","volume":"4","author":"Xiao","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2024.116507_b0720","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fendo.2015.00128","article-title":"Activation of relaxin family receptor 1 from different mammalian species by relaxin peptide and small-molecule agonist ML290","volume":"6","author":"Huang","year":"2015","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"6","key":"10.1016\/j.bcp.2024.116507_b0725","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1210\/js.2017-00112","article-title":"Human relaxin receptor is fully functional in humanized mice and is activated by small molecule agonist ML290","volume":"1","author":"Kaftanovskaya","year":"2017","journal-title":"J. Endocr. Soc."},{"issue":"11","key":"10.1016\/j.bcp.2024.116507_b0730","doi-asserted-by":"crossref","first-page":"12435","DOI":"10.1096\/fj.201901046R","article-title":"Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis","volume":"33","author":"Kaftanovskaya","year":"2019","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0735","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1038\/s41598-017-02916-5","article-title":"ML290 is a biased allosteric agonist at the relaxin receptor RXFP1","volume":"7","author":"Kocan","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0740","doi-asserted-by":"crossref","first-page":"10806","DOI":"10.1038\/s41598-017-10521-9","article-title":"In search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosis","volume":"7","author":"McBride","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2024.116507_b0745","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.650769","article-title":"ANTI-apoptotic and matrix remodeling actions of a small molecule agonist of the human relaxin receptor, ML290 in mice with unilateral ureteral obstruction","volume":"12","author":"Ng","year":"2021","journal-title":"Front. Physiol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116507_b0750","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1021\/acs.jmedchem.3c02183","article-title":"Identification of novel series of potent and selective relaxin family peptide receptor 1 (RXFP1) agonists","volume":"67","author":"Granberg","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2024.116507_b0755","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1021\/acs.jmedchem.3c02184","article-title":"Discovery of clinical candidate AZD5462, a selective oral allosteric RXFP1 agonist for treatment of heart failure","volume":"67","author":"Granberg","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116507_b0760","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.mce.2019.01.009","article-title":"Relaxin gene therapy: A promising new treatment option for various diseases with aberrant fibrosis or irregular angiogenesis","volume":"487","author":"Hong","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"issue":"5","key":"10.1016\/j.bcp.2024.116507_b0765","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","article-title":"Interleukin 12: still a promising candidate for tumor immunotherapy?","volume":"63","author":"Lasek","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2024.116507_b0770","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mce.2007.09.008","article-title":"Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis","volume":"280","author":"Bathgate","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2024.116507_b0775","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijcard.2016.05.011","article-title":"Relaxin-2 improves diastolic function of pressure-overloaded rats via phospholamban by activating Akt","volume":"218","author":"Shuai","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0780","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jacbts.2021.10.012","article-title":"Cardiac gene therapy with relaxin receptor 1 overexpression protects against acute myocardial infarction","volume":"7","author":"Devarakonda","year":"2022","journal-title":"JACC Basic Transl. Sci."},{"issue":"1\u20133","key":"10.1016\/j.bcp.2024.116507_b0785","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jgm.2872","article-title":"A single adenovirus-mediated relaxin delivery attenuates established liver fibrosis in rats","volume":"18","author":"Kim","year":"2016","journal-title":"J. Gene Med."},{"issue":"8","key":"10.1016\/j.bcp.2024.116507_b0790","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb6596","article-title":"Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy","volume":"7","author":"Zhou","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.bcp.2024.116507_b0795","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41467-019-10893-8","article-title":"Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy","volume":"10","author":"Hu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2024.116507_b0800","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.biomaterials.2016.04.025","article-title":"Human relaxin gene expression delivered by bioreducible dendrimer polymer for post-infarct cardiac remodeling in rats","volume":"97","author":"Lee","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.bcp.2024.116507_b0805","article-title":"Cellular delivery of relaxin-2 mRNA as a potential treatment for kidney fibrosis","volume":"21","author":"Ding","year":"2023","journal-title":"Mater Today Biol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116507_b0810","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41565-020-00836-6","article-title":"Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis","volume":"16","author":"Hu","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bcp.2024.116507_b0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116136","article-title":"Periodic injections of Relaxin 2, its pharmacokinetics and remodeling of rat hearts","volume":"223","author":"Gabris-Weber","year":"2024","journal-title":"Biochem. Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224004908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224004908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T17:17:32Z","timestamp":1741713452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224004908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":163,"alternative-id":["S0006295224004908"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116507","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of relaxin or relaxin mimetics in managing cardiovascular complications of diabetes","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116507"}}